Analyst Price Target is $11.00
▲ +482.01% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Catalyst Biosciences in the last 3 months. The average price target is $11.00, with a high forecast of $18.00 and a low forecast of $4.00. The average price target represents a 482.01% upside from the last price of $1.89.
Current Consensus is
The current consensus among 3 investment analysts is to hold stock in Catalyst Biosciences. This rating has held steady since June 2022, when it changed from a Buy consensus rating.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.